Role of Genomic Imprinting in Cancer Diagnosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-01

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current research focus for cancer diagonosis is classical genetics, named "driving genes". However, not all cancer patients have typical genetic alterations, especially at early stage. In the past dacades, accumulating evidences have revealed that more than 80% diseases are closely related to epigenetic changes. The normally silenced copy of imprinted genes are reactivated at early stage of cancers, and finally proceed to copy number variation. This study will screen for a panel of imprinted genes and build quantitative models to assist the diagnosis of multiple cancers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Study of Pan-cancer DNA Methylation Test in Plasma

NCT05685524

Cancer

UNKNOWN

Pan-canceR Early DetectIon projeCT (PREDICT)

NCT04817306

Cancer

UNKNOWN

Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing

NCT06036563

Cancer Diagnosis LungCancer Gastric Cancer +5 more

RECRUITING

Detection of G-quadruplex DNA Methylation in Cancer

NCT06537063

Cancer DNA G-quadruplex Methylation +1 more

WITHDRAWN

Methylation Biomarkers for Pioneering Early Esophageal Cancer Detection

NCT06895551

Esophageal Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Early Diagnosis Cancer Biomarker Genomic Imprinting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cancer patients

The patients receive the surgery according to the indication of surgery. The diagnosis is confirmed by pathology of removed tissue. The result of imprinting detection are used as cancer group.

In-situ imprinting detection

Intervention Type DIAGNOSTIC_TEST

The loss of imprinting (LOI) and copy number variation (CNV) from biopsies will be tested by LiSen in-situ imprinting detection.

Benign tumor and other disease patients

Patients ruled out the possibility of malignancy according to biopsy pathology are used as negative control.

In-situ imprinting detection

Intervention Type DIAGNOSTIC_TEST

The loss of imprinting (LOI) and copy number variation (CNV) from biopsies will be tested by LiSen in-situ imprinting detection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

In-situ imprinting detection

The loss of imprinting (LOI) and copy number variation (CNV) from biopsies will be tested by LiSen in-situ imprinting detection.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with suspicious cancer by ultrasound, CT or endoscope.
* Biopsy samples available.
* Male or female patients aged ≥ 18 years.
* Participants signed informed consent form.

Exclusion Criteria

* Age under 18 years.
* Severe cardiovascular diseases.
* Central nervous system diseases.
* Mental disorder.
* Pregnant.
* Individuals unwilling to sign the IRB-approved consent form and unwilling to follow the protocol to submit the serial urine for test after surgery.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes